The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.
The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.
Division of Urologic Surgery, Washington University School of Medicine, Washington University in St. Louis, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110, USA. andrioleg@wustl.edu
Gerald L
GL
Andriole
Douglas
D
Reding
Richard B
RB
Hayes
Philip C
PC
Prorok
John K
JK
Gohagan
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000401:mortality; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000401:mortality; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality; D012307:Risk Factors
D014408:Biomarkers, Tumor